Theranexus Shows Promise in Batten Disease Study

Theranexus SA (FR:ALTHX) has released an update.

Theranexus, in collaboration with the Beyond Batten Disease Foundation, reports positive 18-month results from its phase 1/2 study of Batten-1, indicating a significant decrease in neurofilament light chains, a key biomarker of neuronal death in juvenile Batten disease. The consistent findings highlight the therapeutic potential of Batten-1, with plans to proceed to pivotal phase 3 trials in Europe and the US. Additionally, a compassionate access program has been implemented for ongoing patient treatment.

For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.